Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

RAM V Nampoothiri, MDDM MRCP (UK), Carol Chen, Zeyad Al-Shaibani, MD, Ivan Pasic, MDPhD, Arjun Law, MD, Wilson Lam, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD, Santhosh Thyagu, MDDM

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142982

Published: 2020

Journal Articles

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Remberger Mats, PhD, Carol Chen, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Rajat Kumar, MD, Fotios Michelis, MD PhD, Jonas Mattsson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139736

Published: 2020

Journal Articles

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

RAM V Nampoothiri, MDDM MRCP (UK), Lina Ho, Cassandra McEwan, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142302

Published: 2020

Journal Articles

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138927

Published: 2020

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Maria Queralt Salas, MD, Arjun Law, MDDM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, David Loach, MD, Zeyad Al-Shaibani, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 3344.

https://doi.org/10.1182/blood-2019-128639

Published: 2019

Journal Articles

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Maria Queralt Salas, MD, Eshetu G Atenafu, M.Sc., P.Stat, Ora Bascom, Allo-HSCT Coordinator, Leeann Wilson, RN, BSc, BSc N(HON), CON(c), Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Jonas Mattsson, MD, Alibhai M.H. Shabbir, MD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 380.

https://doi.org/10.1182/blood-2019-126071

Published: 2019

Journal Articles

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Kyoung Ha Kim, MD PhD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Zeyad Al-Shaibani, Arjun Law, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Zhaolei Zhang, PhD, Tamir Biezuner, PhD, Liran I. Shlush, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4514.

https://doi.org/10.1182/blood-2019-129497

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Maria Queralt Salas, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Zeyad Al-Shaibani, David Loach, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 4594.

https://doi.org/10.1182/blood-2019-128720

Published: 2019

Journal Articles

Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT

Maria Queralt Salas, MD, Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 5669.

https://doi.org/10.1182/blood-2019-128532

Published: 2019

Journal Articles

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

RAM V Nampoothiri, Arjun Law, MD, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MD

Blood (2019) 134 (Supplement_1): 5737.

https://doi.org/10.1182/blood-2019-128445

Published: 2019

Journal Articles

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

RAM V Nampoothiri, Arjun Law, MDDM, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 5717.

https://doi.org/10.1182/blood-2019-124834

Published: 2019

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Maria Rhida Bautista, MD FRACP, FRCPA, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2018-99-119472

Published: 2018

Journal Articles

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Shruti Prem Sudha, MD DM, Eshetu G Atenafu, M.Sc., P.Stat, Queralt Salas Gay, MD, Zoe Evans, Zeyad Al-Shaibani, MD, David Loach, MD, Arjun Law, MDDM, Wilson Lam, MD, Santhosh Thyagu, MD DM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MD DM

Blood (2018) 132 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2018-99-111955

Published: 2018

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only